We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

August 20, 2021

How has COVID-19 Shaped DTx for the Mental Health Market?

Commentary
Nadia Worgan
&

How has COVID-19 Shaped DTx for the Mental Health Market?

The prevalence of mental health conditions had been relatively stable before 2020, however, this trend changed at the onset of the COVID-19 pandemic. Globally, the mental health of the population deteriorated. According to the OECD, the prevalence of both anxiety and depression increased rapidly around the world, and in some countries, it doubled since the start of the pandemic, especially during periods of high COVID-19 deaths and strict regulations. These conditions affect one in five people, but between 30-40% of those needing treatment for these disorders do not receive it. However, DTx can serve as a mitigating factor for this trend.

During the pandemic, the delivery of these essential mental health services was disrupted and so health care professionals quickly needed to change their modes of delivery. Mitigation strategies for these disruptions included switching to remote care, digital platforms and telemedicine

Digital Therapeutics (DTx) serves as a potential solution for this need to address the growing demand for mental health services and deliver personalised treatment interventions. The treatment outcomes for mental health are intrinsically subjective and so digital tools can help to improve this by collecting and monitoring digital biomarkers (consumer-generated physiological and behavioural measures). 

Our HealthXL insights show that a  successful route to market for DTx mental health solutions is through partnerships. Employer and insurance partnerships have shown to be successful routes to market, and following this, pharmacy and hospital partnerships also hold great potential. However, as DTx for mental health is a relatively new solution, there are some key challenges in adopting this such as: low rates of reimbursement, building significant evidence to support their clinical benefits, patient engagement and finally, physician time and awareness. 

Despite these challenges, many companies have seen the potential of the mental health DTx market and are becoming increasingly active in this space by launching new platforms or by making significant investments in this area.

Ro, a direct-to-consumer virtual care company, is rolling out a new mental health platform called Ro Mind. This will initially focus on generalised anxiety disorder (GAD) and major depressive disorder (MDD). This service offers patients access to US-licensed providers who can, if appropriate, diagnose and prescribe FDA-approved prescription treatments for anxiety and depression. Ro Mind also works with patients to manage these treatments and track their progress on a regular basis. If patients are prescribed medication, they are supported by Ro’s nationwide pharmacy network. Ro pharmacies coordinate care with providers to adjust dosing and ensure patients receive the appropriate medication when needed. Ro also supports patients by offering psychoeducation through virtual sessions at no extra cost. Ro is also planning to launch more services, including individual and group therapy.

Happify Health has announced the launch of Ensemble, this is the first and only transdiagnostic prescription digital therapeutic for the treatment of patients who have GAD or MDD. Ensemble is prescribed by a clinician to treat these disorders, it delivers skills training based on cognitive behavioural therapy (CBT), mindfulness and related forms of behavioural science-based techniques and activities designed to treat symptoms of MDD and GAD.

Amwell, a national telehealth leader, has recently acquired SilverCloud Health, a leading digital mental health platform. SilverCloud Health offers a range of digital cognitive behavioural health programs which are evidence-based and clinically validated. Their programs have shown results equivalent to face-to-face care for the one in five with diagnosable mental health conditions. Amwell will be able to leverage SilverCloud’s platform to expand its own behavioural health offerings and develop new digital specialty care programs. 

Woebot Health recently announced that they have closed a $90 million Series B funding round to advance their relational platform and digital therapeutics for mental health to meet the increasing global demand for these services.

In order to establish product integrity and confirm patient safety, all DTx products should adhere to the Industry Core Principles which are utilised as a guide for best practice to end users, clinicians and payors as they investigate the efficacy and safety of DTx products. These principles state that DTx products should publish clinical trial results, incorporating meaningful outcomes and peer-reviewed journals. They should be reviewed and cleared or approved by regulatory bodies as required to support product claims of risk, efficacy and intended use. The products should only make claims appropriate to clinical evaluation and regulatory status. DTx products should collect, analyse and apply real world evidence and product performance data. 

The current capacity for mental health services is buckling under the evident cumulative rise in demand for these services. Digital Therapeutics offer the ultimate solution by expanding capacity to offer these services via technology in a clinically effective and safe way, to reach more people who need support.

Are you interested in learning more about Digital Therapeutics for Mental Health? Join your peers at our upcoming digital health meeting on September 7th, 23rd and 28th.



We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Key Considerations for Inclusion on the Evernorth Digital Health Formulary

13th December @ 10:45AM EDT

How do DTx products get listed on a formulary? And what happens next? Join this masterclass to hear from Mark Bini, the visionary who helped devise Evernorth's Digital Health Formulary.

Featuring
Mark Bini
Mark Bini
Chief Patient Experience Officer at Evernorth
Featuring
Mark Bini
Mark Bini
Chief Patient Experience Officer at Evernorth
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Future EU Regulations for AI in Medical Devices

13th December @ 10AM GMT / 6PM AWST

Are you trying to commercialize AI-based digital health solutions in the European Union (EU)? Would you like to learn practical steps on how to navigate the EU regulations for AI in medical devices? Join us in this masterclass led by Erik Vollebregt (Partner at Axon Lawyers) to deep dive into this topic.

Featuring
Erik Vollebregt
Erik Vollebregt
Partner, Axon Lawyers
Featuring
Erik Vollebregt
Erik Vollebregt
Partner, Axon Lawyers
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Innovative Distribution Strategies for DTx

14th December @ 10:45 AM EDT

Currently, there is no one-size-fits-all strategy for DTx distribution. Join HealthXL in this meeting to discuss this topic further with your peers working in this space.

Featuring
Francesca Wuttke
Francesca Wuttke
CEO and Founder, nen Health
Featuring
Francesca Wuttke
Francesca Wuttke
CEO and Founder, nen Health
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: DTx Access Negotiation and Contracting with Commercial Health Plans in the US

15th December @ 10:45 AM EDT

Are you seeking reimbursement of a DTx solution in the US? Join this Masterclass led by Mike Pace to deep dive into this topic with your peers working in this space.

Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Telemedicine & Virtual Care Delivery
12th December @ 10:45AM EDT

Masterclass: Partnering with Health Systems in Digital Health

Are you working in digital health and looking for successful partnerships with health systems? Join this meeting to deep dive into this topic with other senior leaders in this field.

Michael Freni
Featuring
Michael Freni
Vice President, Business Development, Innovation & Venture Partner, A.I. Digital Innovation Fund, Mass General Brigham
Digital Therapeutics (DTx)
13th December @ 10:45AM EDT

Masterclass: Key Considerations for Inclusion on the Evernorth Digital Health Formulary

How do DTx products get listed on a formulary? And what happens next? Join this masterclass to hear from Mark Bini, the visionary who helped devise Evernorth's Digital Health Formulary.

Mark Bini
Featuring
Mark Bini
Chief Patient Experience Officer at Evernorth
Digital Therapeutics (DTx)
13th December @ 10AM GMT / 6PM AWST

Masterclass: Future EU Regulations for AI in Medical Devices

Are you trying to commercialize AI-based digital health solutions in the European Union (EU)? Would you like to learn practical steps on how to navigate the EU regulations for AI in medical devices? Join us in this masterclass led by Erik Vollebregt (Partner at Axon Lawyers) to deep dive into this topic.

Erik Vollebregt
Featuring
Erik Vollebregt
Partner, Axon Lawyers
Digital Therapeutics (DTx)
14th December @ 10:45 AM EDT

Innovative Distribution Strategies for DTx

Currently, there is no one-size-fits-all strategy for DTx distribution. Join HealthXL in this meeting to discuss this topic further with your peers working in this space.

Francesca Wuttke
Featuring
Francesca Wuttke
CEO and Founder, nen Health

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.